Cargando…

Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy

Venetoclax is approved as monotherapy and in combination with rituximab for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Two Phase 1 studies (M12‐175 [NCT01328626]; M13‐365 [NCT01682616]) were conducted in which patients who initially responded and then progressed on venetoclax mono...

Descripción completa

Detalles Bibliográficos
Autores principales: Handunnetti, Sasanka, Anderson, Mary Ann, Roberts, Andrew W., Davids, Matthew S., Ma, Shuo, Boyer, Michelle, Arzt, Jennifer, Masud, Abdullah Al, Popovic, Relja, Jacobson, Amanda, Kim, Su Y., Seymour, John F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175959/
https://www.ncbi.nlm.nih.gov/pubmed/35845292
http://dx.doi.org/10.1002/jha2.177
_version_ 1784722559737004032
author Handunnetti, Sasanka
Anderson, Mary Ann
Roberts, Andrew W.
Davids, Matthew S.
Ma, Shuo
Boyer, Michelle
Arzt, Jennifer
Masud, Abdullah Al
Popovic, Relja
Jacobson, Amanda
Kim, Su Y.
Seymour, John F.
author_facet Handunnetti, Sasanka
Anderson, Mary Ann
Roberts, Andrew W.
Davids, Matthew S.
Ma, Shuo
Boyer, Michelle
Arzt, Jennifer
Masud, Abdullah Al
Popovic, Relja
Jacobson, Amanda
Kim, Su Y.
Seymour, John F.
author_sort Handunnetti, Sasanka
collection PubMed
description Venetoclax is approved as monotherapy and in combination with rituximab for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Two Phase 1 studies (M12‐175 [NCT01328626]; M13‐365 [NCT01682616]) were conducted in which patients who initially responded and then progressed on venetoclax monotherapy could receive added rituximab. Ten patients were evaluated (M12‐175, n = 8; M13‐365, n = 2), and five (50%) responded again upon addition of rituximab, including three complete and two partial responses. Responses were ongoing after 5–10 months of follow‐up. Addition of rituximab was well tolerated. These findings indicate potential clinical benefit with rituximab added to venetoclax post‐progression in some patients with R/R CLL.
format Online
Article
Text
id pubmed-9175959
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-91759592022-07-14 Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy Handunnetti, Sasanka Anderson, Mary Ann Roberts, Andrew W. Davids, Matthew S. Ma, Shuo Boyer, Michelle Arzt, Jennifer Masud, Abdullah Al Popovic, Relja Jacobson, Amanda Kim, Su Y. Seymour, John F. EJHaem Short Reports Venetoclax is approved as monotherapy and in combination with rituximab for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). Two Phase 1 studies (M12‐175 [NCT01328626]; M13‐365 [NCT01682616]) were conducted in which patients who initially responded and then progressed on venetoclax monotherapy could receive added rituximab. Ten patients were evaluated (M12‐175, n = 8; M13‐365, n = 2), and five (50%) responded again upon addition of rituximab, including three complete and two partial responses. Responses were ongoing after 5–10 months of follow‐up. Addition of rituximab was well tolerated. These findings indicate potential clinical benefit with rituximab added to venetoclax post‐progression in some patients with R/R CLL. John Wiley and Sons Inc. 2021-03-03 /pmc/articles/PMC9175959/ /pubmed/35845292 http://dx.doi.org/10.1002/jha2.177 Text en © 2021 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Reports
Handunnetti, Sasanka
Anderson, Mary Ann
Roberts, Andrew W.
Davids, Matthew S.
Ma, Shuo
Boyer, Michelle
Arzt, Jennifer
Masud, Abdullah Al
Popovic, Relja
Jacobson, Amanda
Kim, Su Y.
Seymour, John F.
Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
title Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
title_full Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
title_fullStr Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
title_full_unstemmed Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
title_short Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
title_sort addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapy
topic Short Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9175959/
https://www.ncbi.nlm.nih.gov/pubmed/35845292
http://dx.doi.org/10.1002/jha2.177
work_keys_str_mv AT handunnettisasanka additionofrituximabinrelapsedrefractorychroniclymphocyticleukemiaafterprogressiononvenetoclaxmonotherapy
AT andersonmaryann additionofrituximabinrelapsedrefractorychroniclymphocyticleukemiaafterprogressiononvenetoclaxmonotherapy
AT robertsandreww additionofrituximabinrelapsedrefractorychroniclymphocyticleukemiaafterprogressiononvenetoclaxmonotherapy
AT davidsmatthews additionofrituximabinrelapsedrefractorychroniclymphocyticleukemiaafterprogressiononvenetoclaxmonotherapy
AT mashuo additionofrituximabinrelapsedrefractorychroniclymphocyticleukemiaafterprogressiononvenetoclaxmonotherapy
AT boyermichelle additionofrituximabinrelapsedrefractorychroniclymphocyticleukemiaafterprogressiononvenetoclaxmonotherapy
AT arztjennifer additionofrituximabinrelapsedrefractorychroniclymphocyticleukemiaafterprogressiononvenetoclaxmonotherapy
AT masudabdullahal additionofrituximabinrelapsedrefractorychroniclymphocyticleukemiaafterprogressiononvenetoclaxmonotherapy
AT popovicrelja additionofrituximabinrelapsedrefractorychroniclymphocyticleukemiaafterprogressiononvenetoclaxmonotherapy
AT jacobsonamanda additionofrituximabinrelapsedrefractorychroniclymphocyticleukemiaafterprogressiononvenetoclaxmonotherapy
AT kimsuy additionofrituximabinrelapsedrefractorychroniclymphocyticleukemiaafterprogressiononvenetoclaxmonotherapy
AT seymourjohnf additionofrituximabinrelapsedrefractorychroniclymphocyticleukemiaafterprogressiononvenetoclaxmonotherapy